Hello friends and colleagues, As we reflect on Women’s History Month, we would like to take the opportunity to shine a spotlight on...

Hello friends and colleagues, As we close out a short month packed with major updates and announcements, we are using this Leap Day to...

Greetings friends and colleagues, Happy New Year and welcome to our first newsletter of 2024! As we usher in another promising year, we...

Dear Readers, As our economy continues to change, we thought it would be helpful to share some insights and industry patterns that we...

Dear friends and colleagues, “Biotech’s flameout,” “bloodbath,” “thousands of layoffs.” We’ve all heard it, and we’re in it. Whether...

To help our readers prepare for their next financing round, we’ve compiled a list of the 5 must-have slides for any investor pitch deck....

Dear Readers, As we gear up for conference season, we thought it could be helpful to share some tips on how to succeed while at a...

Many of our clients are pursuing groundbreaking therapies in disease areas with high unmet medical needs, giving our firm the chance to...

One of our most sought-after commercial strategy services is the creation of revenue forecasts. As such, we’ve spent numerous projects...

Our work at Headland covers a wide range of diseases and therapeutic areas, and we try to stay abreast of recent news and developments in...

As we’ve expanded our US-Japan services, we are often asked about the differences between the US and Japanese biopharma industry. There...

Last month we attended the first completely virtual BIO conference. We met with many innovative companies and are looking forward to...

A note from our CEO, President, and Founder: My team and I are deeply troubled by the ongoing examples of violence, cruelty, and...